Lupin: USFDA Inspects Lupin's Largest Goa Facility, Raises Concerns About Quality Control Issues - CNBC TV18

 19 Feb 2026 10:59 AM

Lupin: USFDA Inspects Lupin's Largest Goa Facility, Raises Concerns About Quality Control Issues - CNBC TV18

Lupin: Company Partners With Spektus To Distribute New Antidepressant Deslaflex In Canada

 16 Feb 2026 05:41 PM

Lupin: Company Partners With Spektus To Distribute New Antidepressant Deslaflex In Canada

Citi maintains 'Buy' ratings on Lupin, hikes target price to Rs 2,540.

 16 Feb 2026 09:00 AM

Citi maintains 'Buy' ratings on Lupin, hikes target price to Rs 2,540.

MorganStanley's call on Lupin: Equal-weight call, target price at ₹2,386/sh

 16 Feb 2026 09:02 AM

MorganStanley's call on Lupin: Equal-weight call, target price at ₹2,386/sh

Nomura maintains buy on Lupin with a target price of ₹2,580

 16 Feb 2026 09:03 AM

Nomura maintains buy on Lupin with a target price of ₹2,580

Lupin: Company Raises Full-Year FY26 EBITDA Margin Guidance To 27%-28% From 25%-26%, Though Q4 Margins May Be Affected By Higher R&D Costs And Lower PLI Income. For FY27, The Company Predicts EBITDA Margins At 24%-25% While Expecting Steady Revenue Growth And A Focus On Costs Despite Risks From Product Competition And Rising R&D Expenses.

 16 Feb 2026 08:38 AM

Lupin: Company Raises Full-Year FY26 EBITDA Margin Guidance To 27%-28% From 25%-26%, Though Q4 Margins May Be Affected By Higher R&D Costs And Lower PLI Income. For FY27, The Company Predicts EBITDA Margins At 24%-25% While Expecting Steady Revenue Growth And A Focus On Costs Despite Risks From Product Competition And Rising R&D Expenses.

Lupin: India Formulations Business Expected to Be 1.2X to 1.3X Ahead of Indian Pharmaceutical Market, Boosted by Strong Sales and 80+ New Products. Company Plans to Invest $250 Million to $300 Million in Specialty Assets, Focusing on Acquisitions in Developed Markets.

 16 Feb 2026 08:38 AM

Lupin: India Formulations Business Expected to Be 1.2X to 1.3X Ahead of Indian Pharmaceutical Market, Boosted by Strong Sales and 80+ New Products. Company Plans to Invest $250 Million to $300 Million in Specialty Assets, Focusing on Acquisitions in Developed Markets.

Lupin: Management Anticipates Double-Digit Growth of 20% to 30% in India, Outpacing Market's 7% to 8% Annual Growth. Key Growth Factors Include Resolved Past Exclusivities, Insulin Opportunities, and Upcoming Semaglutide Launch.

 16 Feb 2026 08:38 AM

Lupin: Management Anticipates Double-Digit Growth of 20% to 30% in India, Outpacing Market's 7% to 8% Annual Growth. Key Growth Factors Include Resolved Past Exclusivities, Insulin Opportunities, and Upcoming Semaglutide Launch.

Lupin: Company Plans First 505(B)(2) Products Launch in FY27 and Exclusive XYWAV Product Launch in FY29. Injectable Portfolio, Including Dalbavancin, Eribulin, and Iron Sucrose, Expected to Exceed $100 Million in Three Years.

 16 Feb 2026 08:38 AM

Lupin: Company Plans First 505(B)(2) Products Launch in FY27 and Exclusive XYWAV Product Launch in FY29. Injectable Portfolio, Including Dalbavancin, Eribulin, and Iron Sucrose, Expected to Exceed $100 Million in Three Years.

Lupin: Company Increases FY26 Margin Guidance From 25-26% To 27-28% - CNBCTv18

 13 Feb 2026 12:31 PM

Lupin: Company Increases FY26 Margin Guidance From 25-26% To 27-28% - CNBCTv18

Morgan Stanley maintains 'Equal-weight' ratings on Lupin with a target price of Rs 2,211

 13 Feb 2026 09:05 AM

Morgan Stanley maintains 'Equal-weight' ratings on Lupin with a target price of Rs 2,211

LUPIN: Q3 CONS NET PROFIT 11.76B RUPEES VS 8.55B (YOY); EST 12.03B || Q3 REVENUE 71B RUPEES VS 57.7B (YOY); EST 67.8B

 12 Feb 2026 09:35 PM

LUPIN: Q3 CONS NET PROFIT 11.76B RUPEES VS 8.55B (YOY); EST 12.03B || Q3 REVENUE 71B RUPEES VS 57.7B (YOY); EST 67.8B

LUPIN: Q3 EBITDA 22.6B RUPEES VS 13.56B (YOY); EST 19.02B || Q3 EBITDA MARGIN 31.56% VS 23.5% (YOY); EST 28%

 12 Feb 2026 09:36 PM

LUPIN: Q3 EBITDA 22.6B RUPEES VS 13.56B (YOY); EST 19.02B || Q3 EBITDA MARGIN 31.56% VS 23.5% (YOY); EST 28%

Lupin: Company Settles Patent Dispute With Astellas Over Mirabegron, Will Pay USD 90 Million Plus Per-Unit License Fee Until September 2027

 10 Feb 2026 08:30 AM

Lupin: Company Settles Patent Dispute With Astellas Over Mirabegron, Will Pay USD 90 Million Plus Per-Unit License Fee Until September 2027

Lupin: Company and its U.S. branch have settled a patent dispute with Astellas regarding Lupin's Mirabegron product. The company will pay $90 million, including a $75 million upfront payment, plus a per-unit fee for each unit sold until September 2027, with additional terms kept confidential.

 10 Feb 2026 08:30 AM

Lupin: Company and its U.S. branch have settled a patent dispute with Astellas regarding Lupin's Mirabegron product. The company will pay $90 million, including a $75 million upfront payment, plus a per-unit fee for each unit sold until September 2027, with additional terms kept confidential.

Lupin: Company Launches Topiramate Extended-Release Capsules In The U.S. With Estimated Annual Sales Of USD 164 Million

 04 Feb 2026 08:49 PM

Lupin: Company Launches Topiramate Extended-Release Capsules In The U.S. With Estimated Annual Sales Of USD 164 Million

Lupin: Co Launches Dasatinib Tablets In The U.S. After FDA Approval, Available In Dosages Of 20 MG, 50 MG, 70 MG, 80 MG, 100 MG, And 140 MG; Expected Annual Sales Reach USD 930 Million.

 02 Feb 2026 11:04 AM

Lupin: Co Launches Dasatinib Tablets In The U.S. After FDA Approval, Available In Dosages Of 20 MG, 50 MG, 70 MG, 80 MG, 100 MG, And 140 MG; Expected Annual Sales Reach USD 930 Million.

Lupin: Forms Partnership With TB Alliance To Develop Telacebec For Treating Tuberculosis And Other Mycobacterial Illnesses, Offering Manufacturing And Regulatory Support.

 02 Feb 2026 10:09 AM

Lupin: Forms Partnership With TB Alliance To Develop Telacebec For Treating Tuberculosis And Other Mycobacterial Illnesses, Offering Manufacturing And Regulatory Support.

Lupin: DGTR, In Its Preliminary Findings Concludes That There Is Dumping Of Ethambutol Hydrochloride Imports From China And Thailand, And Flags This As A Material Injury To Domestic Players

 01 Feb 2026 09:04 AM

Lupin: DGTR, In Its Preliminary Findings Concludes That There Is Dumping Of Ethambutol Hydrochloride Imports From China And Thailand, And Flags This As A Material Injury To Domestic Players

Lupin: Partners With :Galenicum For Semaglutide Licensing And Supply In 23 Nations

 21 Jan 2026 08:03 AM

Lupin: Partners With :Galenicum For Semaglutide Licensing And Supply In 23 Nations